Neurodegeneration – Products

A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease.

New free of charge service will offer insights in under ten days to sponsors conducting clinical trials in any indication, identifying potential “zombie trials” and providing actionable recommendations for failing trials.

Newly-launched module set to accelerate drug discovery in therapeutic areas such as neuropsychiatry, epilepsy and neurodegeneration.

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.

AMSBIO, is proud to announce its collaboration with WARR Space Labs, a student group from the Technical University of Munich (TUM).

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.